{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T05:16:17Z","timestamp":1766639777669,"version":"3.48.0"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011755","name":"National Center for Research and Development","doi-asserted-by":"crossref","award":["POIR.04.01.04-00-0025\/20"],"award-info":[{"award-number":["POIR.04.01.04-00-0025\/20"]}],"id":[{"id":"10.13039\/501100011755","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016247","name":"Wroc\u0142aw University of Environmental and Life Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Canine Diffuse Large B-cell Lymphoma (cDLBCL) is characterized by a high prevalence of MHC II DR (DLA-DR) antigen overexpression. Murine anti-pan-DLA-DR monoclonal antibodies (mAbs) B5 and E11 have been previously observed to promote death of cDLBCL cells in vitro and in vivo. Consequently, DLA-DR antigens are considered a prospective target for passive immunotherapy aside from CD20. While infusion of anti-pan MHC II mAbs has demonstrated tumor suppression in cDLBCL xenografted immunodeficient mice, the relative contributions of direct cellular versus immune-mediated mechanisms to this therapeutic effect remain undefined. This study aimed to dissect these potential mechanisms of mAb E11. Methods: Canine lymphoma and leukemia cell lines CLBL1 and CLB70 were incubated with full E11 antibody or its F(ab\u2032)2 and Fab fragments and cell viability was assessed with sub-G1 assay then, NOD-SCID mice were xenotransplanted with 1.5 \u00d7 107 canine CLBL1 cells expressing nanoluciferase and were infused either with mAb E11 or its fragments, each at 1 mg\/kg body mass, twice weekly for three consecutive weeks. Tumor burden was monitored by assessing body weight, nanoluciferase activity in blood, and by flow cytometric analyses of bone marrow tumor cell content. Time to tumor progression (TTP) was calculated based on weight loss and luminescence measurements. Results: We observed cytotoxic activity of monovalent E11-Fab fragments in vitro and in vivo. The mean TTP for mice treated with irrelevant mouse IgG antibodies was 9.8 \u00b1 4.65 days. In contrast, treatment with E11 Fab fragments resulted in a TTP of 19.1 \u00b1 2.67 days, which was similar to that achieved with the full E11 mAb (19.5 \u00b1 1.73 days) and E11 F(ab\u2032)2 fragments (18.1 \u00b1 2.9 days). Conclusions: Our findings demonstrate a potent antibody cytotoxicity mechanism that operates in vivo and is independent of cell surface MHC II crosslinking or Fc engagement. These data support the promising potential of E11-Fab fragments for further clinical development as a therapeutic agent in canine lymphoma.<\/jats:p>","DOI":"10.3390\/cancers18010048","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:22:14Z","timestamp":1766575334000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fab Antibody Fragments to Dog Leukocyte Antigen DR (DLA-DR) Directly Suppress Canine Lymphoma Cell Line Growth In Vitro and in Murine Xenotransplant Model"],"prefix":"10.3390","volume":"18","author":[{"given":"Aleksandra","family":"Studzi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8003-8882","authenticated-orcid":false,"given":"Marek","family":"Pieczka","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Kruszy\u0144ska","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5025-6801","authenticated-orcid":false,"given":"Leszek","family":"Moniakowski","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-0952","authenticated-orcid":false,"given":"Anna","family":"Urbaniak","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-0287","authenticated-orcid":false,"given":"Andrzej","family":"Rapak","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-2706","authenticated-orcid":false,"given":"Arkadiusz","family":"Miazek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","article-title":"Canine lymphoma: A review","volume":"36","author":"Zandvliet","year":"2016","journal-title":"Vet. Q."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Comazzi, S., Marelli, S., Cozzi, M., Rizzi, R., Finotello, R., Henriques, J., Pastor, J., Ponce, F., Rohrer-Bley, C., and R\u00fctgen, B.C. (2018). Breed-associated risks for developing canine lymphoma differ among countries: An European canine lymphoma network study. BMC Vet. Res., 14.","DOI":"10.1186\/s12917-018-1557-2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1939-1676.2008.0133.x","article-title":"Cancer incidence in pet dogs: Findings of the Animal Tumor Registry of Genoa, Italy","volume":"22","author":"Merlo","year":"2008","journal-title":"J. Vet. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1476-5829.2009.00201.x","article-title":"Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO","volume":"8","author":"Vezzali","year":"2010","journal-title":"Vet. Comp. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.vetimm.2005.02.020","article-title":"Lineage differentiation of canine lymphoma\/leukemias and aberrant expression of CD molecules","volume":"106","author":"Wilkerson","year":"2005","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rocha, M.D.C.P., Ara\u00fajo, D., Carvalho, F., Vale, N., Pazzini, J.M., Feliciano, M.A.R., De Nardi, A.B., and Amorim, I. (2025). Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights. Animals, 15.","DOI":"10.3390\/ani15030391"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0300985810363902","article-title":"A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology","volume":"47","author":"Ponce","year":"2010","journal-title":"Vet. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/imr.12238","article-title":"Man\u2019s best friend: What can pet dogs teach us about non-Hodgkin\u2019s lymphoma?","volume":"263","author":"Richards","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_9","first-page":"2562","article-title":"Canine lymphoma as a potential model for experimental therapeutics","volume":"28","author":"Johnson","year":"1968","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: Recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bennett, P., Williamson, P., and Taylor, R. (2023). Review of Canine Lymphoma Treated with Chemotherapy\u2014Outcomes and Prognostic Factors. Vet. Sci., 10.","DOI":"10.3390\/vetsci10050342"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1038\/s41598-020-68470-9","article-title":"Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment","volume":"10","author":"Mizuno","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"J. Vet. Intern. Med."},{"key":"ref_14","unstructured":"Hanif, N., and Anwer, F. (2025, October 20). Rituximab, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK564374\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vetimm.2015.02.004","article-title":"Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma","volume":"164","author":"Rue","year":"2015","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tvjl.2005.03.005","article-title":"The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation","volume":"171","author":"Impellizeri","year":"2006","journal-title":"Vet. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jvim.17080","article-title":"Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma","volume":"38","author":"McLinden","year":"2024","journal-title":"J. Vet. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways","volume":"115","author":"Stein","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014New insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.2507","article-title":"Development of novel monoclonal antibodies to dog leukocyte antigen DR displaying direct and immune-mediated cytotoxicity toward canine lymphoma cell lines","volume":"36","author":"Lisowska","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lisowska, M., Milczarek, M., Ciekot, J., Kutkowska, J., Hildebrand, W., Rapak, A., and Miazek, A. (2019). An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma. Cancers, 11.","DOI":"10.3390\/cancers11101438"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1002\/eji.1830251222","article-title":"Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments","volume":"25","author":"Falcioni","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/0929867324666170817152554","article-title":"Antibody fragments as potential biopharmaceuticals for cancer therapy: Success and limitations","volume":"26","author":"Kholodenko","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"Hammer","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/vco.12257","article-title":"A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics","volume":"15","author":"Pawlak","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8851986","DOI":"10.1155\/2021\/8851986","article-title":"Reevaluation of NOD\/SCID Mice as NK Cell-Deficient Models","volume":"2021","author":"Miao","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114723","DOI":"10.1016\/j.ab.2022.114723","article-title":"Establishment of a luciferase-based method for measuring cancer cell adhesion and proliferation","volume":"650","author":"Jessen","year":"2022","journal-title":"Anal. Biochem."},{"key":"ref_29","unstructured":"Underwood, W., Anthony, R., Cartner, S., Corey, D., Grandin, T., Greenacre, C., Gwaltney-Brant, S., McCrackin, M.A., Meyer, R., and Miller, D. (2013). AVMA Guidelines for the Euthanasia of Animals: 2013 Edition, American Veterinary Medical Association. Available online: https:\/\/www.avma.org\/resources-tools\/avma-policies\/avma-guidelines-euthanasia-animals."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00109-003-0489-9","article-title":"A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules","volume":"81","author":"Nagy","year":"2003","journal-title":"J. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.imbio.2006.05.006","article-title":"The superantigen staphylococcal enterotoxin A (SEA) and monoclonal antibody L243 share a common epitope but differ in their ability to induce apoptosis via MHC-II","volume":"211","author":"Gross","year":"2006","journal-title":"Immunobiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1172\/JCI117699","article-title":"Induction of B cell apoptosis by TH0, but not TH2, CD4+ T cells","volume":"95","author":"He","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Xenaki, K.T., Oliveira, S., and van Bergen En Henegouwen, P.M.P. (2017). Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01287"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0161-5890(96)00085-5","article-title":"Functional activity of staphylococcal enterotoxin a requires interactions with both the alpha and beta chains of HLA-DR","volume":"33","author":"Dowd","year":"1996","journal-title":"Mol. Immunol"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm736","article-title":"Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells","volume":"8","author":"Nagy","year":"2002","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/10428190290026376","article-title":"In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells","volume":"43","author":"Shi","year":"2002","journal-title":"Leuk. Lymphoma"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T05:13:40Z","timestamp":1766639620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010048"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010048","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}